Search

Adrian Trevisan

Dr Adrian Trevisan was integral in the founding of Neurotech and has since retired in 2018. Dr Trevisan is a neurophysiologist with a wide experience in the field of human physiology and medical devices. He was founder, chief executive and chief scientific officer of AAT Research, a group of companies involved in the development of certified medical devices. The company has since rebranded itself as Neurotech International, becoming a public listed company on the Australian Securities Exchange (ASX), and he remained as a non-executive director until June 2018. He has worked on international research projects in England and France and has given presentations at international conferences and congress, as well as holding a visiting lecturing post at the University of Malta and delivering presentations at the Università degli Studi di Milano. Dr Trevisan has benefited from research grants and formed part of research projects under a number of EU and local funding programmes. He is also a research fellow of the Bedfordshire Center for Mental Health Research in association with the University of Cambridge. He is a co-founder and chief executive of Umana Medical Technologies, a developer and manufacturer of patented temporary tattoo sensors that enable patients and medical professionals to monitor vital signs of patients, without the usual restrictions of cables and wires that affect quality of life.
Bio last updated 21 Jul 2018

Article Timeline

Positions - Previous

PositionCompanyYearCompany's current rankWA staff
Founder, Non-Executive Director (April 2017-June 2018); (Executive Director Jan 2016-April 2017, CEO 2011-2016)
Neurotech International
Neurotech International
2011 - 2018184

Directors Interests

CompanyDateTransaction typeNumber of sharesPrice per shareTransaction valueNature of change
Neurotech International23 Nov 2017Issued411,371$0.16$65,819Rights issue

Directors Shareholdings

CompanyDirect sharesIndirect sharesTotal sharesTotal value
Neurotech International20,152,26020,152,260$3,425,884

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
69thBotanix Pharmaceuticals164%106%
77thSportsHero151%-41%
144thUltima United90%5%
679thNeurotech International-36%0%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Revenue

184th↑Neurotech International$104k
207th↓Ultima United$2k
208th↓SportsHero$795
210th↓Mission NewEnergy$5
211th↓Botanix Pharmaceuticals$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer